Released on = June 25, 2007, 8:27 am

Press Release Author = AnaSpec Inc.

Industry = Biotech

Press Release Summary = Leveraging its portfolio of MOG (35-55) and other multiple
sclerosis (MS) experimental autoimmune encephalomyelitis (EAE)-related peptides,
AnaSpec has introduced its new Rabbit Anti-MOG (35-55) antibody.

Press Release Body = June 25, 2007 - San Jose, CA
Leveraging its portfolio of MOG (35-55) and other multiple sclerosis (MS)
experimental autoimmune encephalomyelitis (EAE)-related peptides, AnaSpec has
introduced its new Rabbit Anti-MOG (35-55) antibody.

Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin
superfamily, is expressed exclusively in central nervous system myelin. Recent
studies suggest that MOG may function in the completion, compaction, and maintenance
of myelin in the central nervous system.1 Even though MOG physiological function is
not entirely understood, studies have correlated the immune response of MOG to
autoimmune mediated demyelination in several species.2 MOG is able to induce
encephalitogenic T cell response, autoantibody response, and produce
relapsing-remitting neurological disease with an extensive plaque-like
demyelination.3 The autoantibody response to MOG [anti-MOG protein and anti-MOG
(35-55) peptide] has been seen in MS patients and EAE-induced mice. This phenomenon
suggests that MOG may have an important role in the development of MS and EAE, an
experimental in vivo animal model for MS.4,5

Rabbit anti-MOG (35-55) polyclonal antibody was raised against a synthetic peptide
from the N-terminus corresponding to amino acids 35-55 of mouse and rat MOG. There
is only one amino acid residue difference between the mouse/rat and human MOG
(35-55) peptide. ELISA results show that Anti-MOG (35-55) cross-react with human.
The antibodies were also evaluated by Western blot.

For more information, visit http://www.anaspec.com/products/product.asp?id

Web Site = http://www.anaspec.com

Contact Details = Ping Yang
ping@anaspec.com